Studies have demonstrated that CBD has a low affinity for the CB1 receptors, but even at low concentrations, CBD decreases G-protein activity (3). CB1 receptors are expressed on many glutamatergic synapses that have been implicated in seizure threshold modulation. CBD may act at CB1 receptors to inhibit glutamate release (4). Studies have shown changes in the expression of CB1 receptors during epileptogenesis and after recurrent seizures (5). CB1 receptor expression is upregulated at GABAergic synapses and shown to be downregulated at glutamatergic synapses in epilepsy, contributing to lowering seizure thresholds.
In your internet travels, you may also come across products called “terpsolates.” The manufacturers of these products infuse CBD Isolate with terpenes (but not cannabinoids like THC). These terpenes may enhance the effectiveness of CBD — or maybe they just make it smell good. This may be a good place to point out that not all CBD products are created equal. The industry is still largely unregulated, and the quality and quantity of CBD in a given product will vary wildly. Third-party testing definitely helps to monitor companies’ claims, but it’s still up to you as the consumer to do your homework on the best CBD products.
“Buying from a reputable manufacturer is crucial, because it matters how the plant is cultivated and processed,” Dr. Maroon says. One clue that a company is cutting corners: too low a cost. Good CBD is pricey—a bottle of high-quality capsules is sold in Cohen’s office for $140. But for many, it’s worth the money. Roth spent $60 on her tiny bottle. But when her energy returned the day she started taking CBD, she decided that was a small price to pay.